Stanozolol: Versiyalar orasidagi farq

Vikipediya, ochiq ensiklopediya
Kontent oʻchirildi Kontent qoʻshildi
Stanozolol“ sahifasi tarjima qilib yaratildi
(Farq yoʻq)

13-Dekabr 2022, 14:40 dagi koʻrinishi

Stanozolol (qisqacha Stz ), ko'plab brend nomlari ostida sotiladigan, digidrotestosteron (DHT) dan olingan androgen va anabolik steroid (AAS) dori hisoblanadi. Irsiy anjiyoödemni davolash uchun ishlatiladi.[1][2][3] U 1962-yilda Amerika farmatsevtika kompaniyasi Winthrop Laboratories (Sterling Drug) tomonidan ishlab chiqilgan va AQSh oziq-ovqat va farmatsevtika idorasi tomonidan inson foydalanishi uchun tasdiqlangan, ammo u AQShda sotilmaydi.[3][4] Bundan tashqari , veterinariya tibbiyotida ham qo'llaniladi.[2][3] Stanozolol asosan sotuvda sotilmaydi va faqat bir necha mamlakatlarda mavjud bo'lib qolmoqda.[2][3] Odamlarda og'iz orqali yoki hayvonlarda mushak ichiga in'ektsiya yo'li bilan beriladi.[3]

Aksariyat inyektsion AAS dan farqli o'laroq, stanozolol esterifikatsiya qilinmaydi va suvli suspenziya yoki og'iz tabletkalari shaklida sotiladi.[3] Preparat og'iz orqali qabul qilinganda C17a alkilatsiyasi tufayli yuqori bio-mavjudlikka ega, bu gormonning birinchi o'tishi bilan jigar metabolizmidan omon qolishga imkon beradi.[5][3] Shu sababli stanozolol tabletka shaklida ham sotiladi. [3]

Stanozolol - bu AAS dan biri bo'lib, odatda samaradorlikni oshiruvchi dorilar sifatida qo'llaniladi va Xalqaro yengil atletika federatsiyalari assotsiatsiyasi (IAAF) va boshqa ko'plab sport organlari homiyligida sport musobaqalarida foydalanish taqiqlanadi. Bu diuretik ta'sirga ega bo'lgan anabolik steroid hisoblanadi. Bundan tashqari, stanozolol AQSh ot poygalarida ham cheklangan.[6][7][8]

Tibbiy maqsadlarda foydalanish

Stanozolol venoz etishmovchilikni davolash uchun bir oz muvaffaqiyat bilan ishlatilgan. U qon fibrinolizini rag'batlantiradi va lipodermatoskleroz kabi venoz kasalliklarda yanada rivojlangan teri o'zgarishlarini davolash uchun qo'llaniladi. Bir nechta randomize sinovlar stanozolol bilan lipodermatoskleroz sohasida yaxshilanishni, terining qalinligini kamaytirishni va, ehtimol, yaraning tezroq davolanishini qayd etdi.[9][10] Shuningdek, u irsiy anjiyoödem, osteoporoz va skelet mushaklari shikastlanishini davolash uchun qo'llanilmoqda. [11] [12]

Tibbiy bo'lmagan foydalanish

Stanozolol raqobatbardosh sportchilar, bodibildingchilar va pauerlifterlar tomonidan jismoniy va ishlash samaradorligini oshirish uchun ishlatiladi.[3]

Yon effektlar

Stanozololning yon ta'siri virilizatsiya (maskulinizatsiya), gepatotoksiklik,[3] yurak-qon tomir kasalliklari va gipertenziyani o'z ichiga oladi.

Farmakologiyasi

Farmakodinamikasi

AAS sifatida stanozolol testosteron va DHT kabi androgenlarga o'xshash androgen retseptorlari (AR) agonisti hisoblanadi.[3][13] Uning androgen retseptorlari bilan yaqinligi digidrotestosteronning taxminan 22% ni tashkil qiladi.[14] Stanozolol 5a-reduktaza uchun substrat emas, chunki u allaqachon 5a-qaytarilgan va shuning uchun teri, soch follikulalari va prostata bezi kabi "androgenik" deb ataladigan to'qimalarg ta'sir qilmaydi.[3][13] Bu testosteron bilan solishtirganda anabolik va androgenik faollikning katta nisbatiga olib keladi.[3][13] Bundan tashqari, 5a-qaytarilgan tabiati tufayli stanozolol aromatizatsiya qilinmaydi va shuning uchun ginekomastiya yoki suyuqlikni ushlab turish kabi estrogenik ta'sirlarni keltirib chiqarishga moyil emas.[3][13] Stanozolol ham muhim progestogen faollikka ega emas.[3][13] Uning 17a-metil guruhi mavjudligi sababli, stanozololning metabolizmi sterik tarzda to'sqinlik qiladi, buning natijasida u og'iz orqali faol bo'ladi, garchi gepatotoksik bo'lsa ham.[3][13]

Farmakokinetikasi

Stanozolol yuqori og'zaki bioaktivliki bor, shu tufayli uning C17a alkil guruhi mavjudligi va u natijasida oshqozon-ichak va jigar metabolizm uchun qarshilik ko'rsatadi[15][16][17]. Preparat inson zardobidagi jinsiy gormonlarni bog'lovchi globulinga (SHBG) juda past yaqinlikga ega, bu testosteronning taxminan 5% va DHT ning 1% ni tashkil qiladi. [18] Stanozolol jigarda metabollanadi, natijada glyukuronid va sulfat konjugatlariga aylanadi.[19] Uning biologik yarimparchalanish davri 9 soat ga teng og'iz orqali qabul qilinganda va suvli suspenziya shaklida mushak ichiga in'ektsiya yo'li bilan berilganda 24 soatni tashkil qiladi.[20][21] Mushak ichiga yuborish orqali bir hafta yoki undan ko'proq ta'sir qilish muddati borligi aytiladi.[19]

Kimyoviy tarkibi

Stanozolol, shuningdek, 17a-metil-2 ' H -androst-2-eno[3,2- c ]pirazol-17b-ol sifatida tanilgan, sintetik 17a-alkillangan androstan steroid va 5a-dihidrotestosteron (DHT) hosilasidir. C17a pozitsiyasida metil guruhi va steroid yadrosining A halqasiga biriktirilgan pirazol halqasi.[1]

Tarixi

1962-yilda Stanozolol AQShda Winthrop tomonidan "Winstrol" savdo nomi ostida va Yevropada Winthropning hamkori Bayer tomonidan "Stromba" nomi bilan bozorga chiqarildi.[22]

Shuningdek, 1962-yilda Kefauver Xarris tuzatishi qabul qilindi, unda oziq-ovqat, dori-darmon va kosmetika to'g'risidagi Federal qonunga o'zgartirish kiritilib, dori ishlab chiqaruvchilardan dori vositalarining samaradorligini tasdiqlashdan oldin isbotini taqdim etishlarini talab qiladi.[23] FDA o'zining Dori samaradorligini o'rganishni amalga oshirish (DESI) dasturini o'zgartirishdan oldin kiritilgan dorilarni, shu jumladan stanozololni o'rganish va tartibga solish uchun amalga oshirdi. DESI dasturi 1962-yilgacha bozorda mavjud bo'lgan barcha dori vositalarini samarali, samarasiz yoki qo'shimcha o'rganishga muhtoj deb tasniflash uchun mo'ljallangan edi.[24] FDA Milliy Fanlar Akademiyasining Milliy tadqiqot kengashini DESI dasturi bo'yicha tegishli dori-darmonlar bo'yicha nashrlarni baholash uchun jalb qildi.[25]

1970-yil iyun oyida FDA DESI ostida tuzilgan NAS/NRC hisobotlari asosida ma'lum AAS, shu jumladan stanozolol samaradorligi bo'yicha o'z xulosalarini e'lon qildi. Dorilar qarilik va postmenopozal osteoporozni davolashda qo'shimcha terapiya sifatida samarali deb tasniflangan, ammo faqat yordamchi vosita sifatida va gipofiz mittiligida (mitti uchun maxsus ogohlantirish bilan, "o'sish gormoni ko'proq mavjud bo'lgunga qadar") va sezilarli darajada yo'q. bir qancha boshqa ko'rsatkichlar uchun samaradorlikning isboti. Xususan, FDA stanozolol uchun "tana to'qimalarini qurish jarayonlarini rag'batlantirish va to'qimalarni yo'q qilish jarayonlarini yomon xulqli kasalliklar va surunkali malign bo'lmagan kasalliklar kabi sharoitlarda qo'shimcha vosita sifatida topdi; keksa bemorlarda zaiflik va boshqa zaiflashuvchi kasalliklar; normal metabolizmning o'zgarishiga olib keladigan oshqozon-ichak kasalliklari; operatsiyadan oldingi va operatsiyadan keyingi davrda to'yib ovqatlanmaydigan bemorlarda va travmatizm tufayli yomon xavfli jarrohlik holatlarida foydalanish; chaqaloqlar, bolalar va o'smirlar uchun etarli vaznga ega bo'lmaganlarda qo'llash; yordam berish uchun qo'llab-quvvatlovchi davolash Jarrohlikdan keyingi, infektsiyadan keyingi va rekonvalescent bemorlarda bo'lgani kabi qulay metabolik muvozanatni tiklash yoki saqlash; kasallik jarayonida to'qimalarni yo'qotgan yoki anoreksiya kabi alomatlari bo'lgan operatsiyadan oldingi bemorlarda muhim ahamiyatga ega; kaltsiyni ushlab turish va undan foydalanish; jarrohlik ilovalar; oshqozon-ichak kasalliklari, to'yib ovqatlanmaydigan kattalar va surunkali kasalliklar; bolalar ovqatlanishi l muammolar; prostata saratoni; va endokrin nuqsonlar."[26] FDA Sterlingga stanozololning samaradorligiga dalil bo'lmagan ko'rsatkichlar bo'yicha marketingni to'xtatish uchun olti oy va ikki ko'rsatkich bo'yicha qo'shimcha ma'lumotlarni taqdim etish uchun bir yil muddat berdi.[26]

Stanozolol 50 mg kapsulalari.

Umumiy nomlari

Stanozolol ingliz, nemis, frantsuz va yapon tillarida stanozololning umumiy nomi va uning INN, USAN, USP, BAN, DCF va JAN, stanozololum lotin tilidagi nomi, stanozololo italyan tilidagi nomi va DCIT, va Estanozolol ispancha uning nomi bilan bog'liq.[1][27][2] Androstanazol, androstanazol, stanazol, stanazolol va estanazolol stanozololning norasmiy sinonimlari hisoblanadi.[1][2] U o'zining oldingi rivojlanish kod nomi bilan ham tanilgan WIN-14833.[1][2][27]

Brend nomlari

Stanozolol bo'lgan yoki sotilgan brend nomlariga Anaysynth, Menabol, Neurabol Caps., Stanabolic (veterinariya), Stanazol (veterinariya), Stanol, Stanozolol, Stanztab, Stargate (veterinariya), Stromba, Strombaject, Sungate (veterinariya), Tevabolin kiradi., Winstrol, Winstrol Depot va Winstrol-V (veterinariya) va boshqalar.[1][2]

Qo'shma Shtatlardagi huquqiy maqom

Amerika Qo'shma Shtatlarida, boshqa AAS kabi, stanozolol federal tartibga solish ostida nazorat qilinadigan modda sifatida tasniflanadi; ular 1990-yildagi Jinoyatni nazorat qilish to'g'risidagi qonunning bir qismi sifatida qabul qilingan Anabolik steroidlar to'g'risidagi qonunga muvofiq III-jadvalga boshqariladigan moddalar sifatida kiritilgan.[28] Nyu-Yorkda shtat qonun chiqaruvchi organi AASni DEA III jadvaliga muvofiq tasniflaydi.

Sportda doping

Stanozolol va boshqa sintetik steroidlar birinchi marta 1974-yilda Xalqaro Olimpiya Qo'mitasi va Xalqaro Atletika Federatsiyalari Assotsiatsiyasi tomonidan taqiqlangan, ularni aniqlash usullari ishlab chiqilgandan so'ng.[29]Professional sportchilar tomonidan stanozolol bilan sportda ko'plab doping holatlari ma'lum bo'lgan. Stanozolol ayniqsa postsovet mamlakatlari sportchilari tomonidan keng qo'llaniladi. 2015-yildan boshlab u Butunjahon antidoping agentligi[30] va AQSh antidoping agentligi tomonidan taqiqlangan.[31]

Tadqiqotlar

Stanozolol ürtiker, irsiy anjiyoödem, Raynaud fenomeni, kriyofibrinogenemiya va lipodermatoskleroz kabi bir qator dermatologik sharoitlarni davolashda tekshirilgan.[32]

Manbalar

  1. 1,0 1,1 1,2 1,3 1,4 1,5 Index Nominum 2000: International Drug Directory. Taylor & Francis, 2000 — 961– bet. ISBN 978-3-88763-075-1.  Manba xatosi: Invalid <ref> tag; name "IndexNominum2000" defined multiple times with different content
  2. 2,0 2,1 2,2 2,3 2,4 2,5 2,6 „Stanozolol - Drugs.com“. Manba xatosi: Invalid <ref> tag; name "Drugs.com" defined multiple times with different content
  3. 3,00 3,01 3,02 3,03 3,04 3,05 3,06 3,07 3,08 3,09 3,10 3,11 3,12 3,13 3,14 3,15 Llewellyn, William. Anabolics. Molecular Nutrition Llc, 2011 — 726–737 bet. ISBN 978-0-9828280-1-4.  Manba xatosi: Invalid <ref> tag; name "Llewellyn2011" defined multiple times with different content
  4. „Drugs@FDA: FDA Approved Drug Products“. www.accessdata.fda.gov. Qaraldi: 2016-yil 18-fevral.
  5. „stanozolol (CHEBI:9249)“. www.ebi.ac.uk. Qaraldi: 2020-yil 6-sentyabr.
  6. „Anabolic Steroids Still an Issue in U.S. Horse Racing“. The Horse (2015-yil 13-fevral). Qaraldi: 2020-yil 6-sentyabr.
  7. „Win, Place, and Dope“. Slate (2009-yil 1-may).
  8. Anonymous. „Model Rules Ver 9.5“. ARCI.com. ARCI. Qaraldi: 2021-yil 14-mart.
  9. "Venous lipodermatosclerosis: treatment by fibrinolytic enhancement and elastic compression". British Medical Journal 280 (6206): 7–11. January 1980. doi:10.1136/bmj.280.6206.7. PMID 6986945. PMC 1600523. //www.pubmedcentral.nih.gov/articlerender.fcgi?tool=pmcentrez&artid=1600523. 
  10. "Efficacy of fibrinolytic enhancement with stanozolol in the treatment of venous insufficiency". The Australian and New Zealand Journal of Surgery 61 (4): 306–9. April 1991. doi:10.1111/j.1445-2197.1991.tb00217.x. PMID 2018441. 
  11. "Hereditary angioedema: Safety of long-term stanozolol therapy". The Journal of Allergy and Clinical Immunology 120 (3): 654–8. September 2007. doi:10.1016/j.jaci.2007.06.037. PMID 17765757. 
  12. "Effect of continuous infusion of an anabolic steroid on murine skeletal muscle". Medicine and Science in Sports and Exercise 25 (4): 485–94. April 1993. PMID 8479303. 
  13. 13,0 13,1 13,2 13,3 13,4 13,5 "Pharmacology of anabolic steroids". British Journal of Pharmacology 154 (3): 502–21. June 2008. doi:10.1038/bjp.2008.165. PMID 18500378. PMC 2439524. //www.pubmedcentral.nih.gov/articlerender.fcgi?tool=pmcentrez&artid=2439524. 
  14. Doods, Henri N.. Receptor Data for Biological Experiments: A Guide to Drug Selectivity. Ellis Horwood, 1991 — 250 bet. ISBN 978-0-13-767450-3. 
  15. Maini AA, Maxwell-Scott H, Marks DJ (February 2014). "Severe alkalosis and hypokalemia with stanozolol misuse". The American Journal of Emergency Medicine. 32 (2): 196.e3–4. doi:10.1016/j.ajem.2013.09.027. PMID 24521609. This case is important as stanozolol misuse is relatively common, due to its high oral bioavailability and perceived safety profile compared with other parenteral AAS.
  16. Bilezikian, John P.. Principles of Bone Biology, Two-Volume Set. Academic Press, 19 January 2002 — 1455– bet. ISBN 978-0-08-053960-7. „Androgenic compounds rendered resistant to gastrointestinal and liver metabolism by containing an alkyl group at the C17α position, such as stanozolol, are orally active.“ 
  17. Herron, Abigail. The ASAM Essentials of Addiction Medicine. Wolters Kluwer Health, 18 March 2015 — 262– bet. ISBN 978-1-4963-1067-5. „Testosterone has low oral bioavailability with only about half of an oral dose available after hepatic first-pass metabolism. Some analogues of testosterone (e.g., methyltestosterone, fluoxymesterone, oxandrolone, and stanozolol) resist such metabolism, so they can be given orally in smaller doses.“ 
  18. "Relative binding affinity of anabolic-androgenic steroids: comparison of the binding to the androgen receptors in skeletal muscle and in prostate, as well as to sex hormone-binding globulin". Endocrinology 114 (6): 2100–6. June 1984. doi:10.1210/endo-114-6-2100. PMID 6539197. 
  19. 19,0 19,1 Hsu WH (25 April 2013). Handbook of Veterinary Pharmacology. John Wiley & Sons. pp. 404–. ISBN 978-1-118-71416-4.
  20. Ruiz P, Strain EC (2011). Lowinson and Ruiz's Substance Abuse: A Comprehensive Textbook. Lippincott Williams & Wilkins. pp. 358–. ISBN 978-1-60547-277-5.
  21. Thieme, Detlef. Doping in Sports. Springer Science & Business Media, 18 December 2009 — 166– bet. ISBN 978-3-540-79088-4. „The oral form is marketed for human use whereas an aqueous suspension for injection is used in the veterinary field.“ 
  22. "Stanozolol, a new anabolic steroid". The Journal of New Drugs 2: 50–5. 1962. doi:10.1177/009127006200200106. PMID 14464563. 
  23. „Promoting Safe and Effective Drugs for 100 Years“. The Kefauver-Harris Drug Amendments. U.S. Food and Drug Administration.
  24. „FDA aims to remove unapproved drugs from market: Risk-based enforcement program focuses on removing potentially harmful products“. Pharmacy Today. United States Food and Drug Administration (2008-yil avgust).
  25. „The Drug Efficacy Study of the National Research Council's Division of Medical Sciences, 1966-1969“. National Academies of Sciences archives..
  26. 26,0 26,1 "Food and Drug Administration Notice.DESI 7630. Certain Anabolic Steroids. Drugs for Human Use: Drug Efficacy Study Implementation". Federal Register 35 (122): 10327–28. 24 June 1970. https://archive.org/details/federalregister35cunit. 
  27. 27,0 27,1 Concise Dictionary of Pharmacological Agents: Properties and Synonyms. Springer Science & Business Media, 6 December 2012 — 261– bet. ISBN 978-94-011-4439-1. 
  28. Karch, Steven B.. Pathology, Toxicogenetics, and Criminalistics of Drug Abuse. CRC Press, 2007. ISBN 978-1-4200-5456-9. 
  29. „Abuse of Androgens and Detection of Illiegal Use Chapter 24“,Testosterone: Action, Deficiency, Substitution. Cambridge University Press, 2004. ISBN 978-1-139-45221-2. 
  30. Ozcagli, Eren; Kara, Mehtap; Kotil, Tugba; Fragkiadaki, Persefoni; Tzatzarakis, Manolis N.; Tsitsimpikou, Christina; Stivaktakis, Polychronis D.; Tsoukalas, Dimitrios et al. (July 2018). "Stanozolol administration combined with exercise leads to decreased telomerase activity possibly associated with liver aging". International Journal of Molecular Medicine 42 (1): 405–413. doi:10.3892/ijmm.2018.3644. ISSN 1107-3756. PMID 29717770. PMC 5979936. //www.pubmedcentral.nih.gov/articlerender.fcgi?tool=pmcentrez&artid=5979936. 
  31. „What is Stanozolol? Education, Science, Spirit of Sport / April 29, 2015“. www.usada.org (2015-yil 29-aprel). Qaraldi: 2020-yil 6-sentyabr.
  32. "Stanozolol as a novel therapeutic agent in dermatology". Journal of the American Academy of Dermatology 33 (2 Pt 1): 254–8. August 1995. doi:10.1016/0190-9622(95)90244-9. PMID 7622653.